EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Isolation, Characterization, and In Vivo Evaluation Efficacy of Lytic Bacteriophage SEP1 Against Salmonella Paratyphi C

Zhiyi Ge, Di Lian, Wei Zhao, Weiru Song iD, Shengyi Han iD, Chunyan Xu

Viruses · 07.07.2026 · 18 (7) · 751

DOI: 10.3390/v18070751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 07.07.2026. Verfasst von Zhiyi Ge und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Animal Science and Technology, Tarim University, Alar 843300, China. Hauptthemen laut MEDLINE: Phage Therapy, Paratyphoid Fever, Salmonella Phages, Bacteriophages. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key R&D Program of Henan Province, Noncommunicable chronic Diseases National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug-resistant Salmonella Paratyphi poses a severe threat to public health. As conventional antibiotics lose efficacy against emerging resistant strains, the need to develop alternative antimicrobial agents has become increasingly urgent. In this study, we isolated and characterized a novel lytic bacteriophage, designated SEP1, from poultry sewage using the S. Paratyphi C strain QH as the host and systematically evaluated its therapeutic potential in a murine infection model Genomic analysis confirmed that SEP1 belongs to the genus Felixounavirus, with an 85,703-bp genome devoid of lysogeny-associated or virulence genes. SEP1 exhibits robust environmental stability, maintaining infectivity at 10–50 °C and pH 4–9; it has a 30 min latent period and a burst size of 133 PFU per infected cell. In vivo, SEP1 treatment conferred 100% survival in infected mice, reduced organ bacterial loads, alleviated tissue damage, and normalized inflammatory cytokine profiles. Collectively, these results demonstrate that SEP1 is a promising candidate for phage therapy targeting S. Paratyphi C infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phage TherapyParatyphoid FeverSalmonella PhagesBacteriophagesAnimalsMiceGenome, ViralDisease Models, AnimalFemalePoultryMice, Inbred BALB C

Stichwörter der Autor:innen

Salmonella Paratyphibacteriophagebiological characteristicsgenomicsphage therapy

Autor:innen und Institutionen

  • College of Animal Science and Technology, Tarim University, Alar 843300, China.
  • Engineering Laboratory of Tarim Animal Diseases Diagnosis and Control, Xinjiang Production & Construction Corps, Alar 843300, China.
  • College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing 100853, China.
  • Center for Animal Disease Control and Prevention, Yushu 815000, China.
  • Academy of Animal Sciences and Veterinary Medicine, Qinghai University, Xining 810016, China.
  • College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China.

ORCID-Profile: Weiru Song, Shengyi Han

Förderung

  • National Natural Science Foundation of China
  • Key R&D Program of Henan Province
  • Noncommunicable chronic Diseases National Science and Technology Major Project

Zitieren

APA

Ge, Z., Lian, D., Zhao, W., Song, W., Han, S., & Xu, C. (2026). Isolation, Characterization, and In Vivo Evaluation Efficacy of Lytic Bacteriophage SEP1 Against Salmonella Paratyphi C. Viruses, 18(7), 751. https://doi.org/10.3390/v18070751

Vancouver

Ge Z, Lian D, Zhao W, Song W, Han S, Xu C. Isolation, Characterization, and In Vivo Evaluation Efficacy of Lytic Bacteriophage SEP1 Against Salmonella Paratyphi C. Viruses. 2026;18(7):751. doi:10.3390/v18070751

BibTeX
@article{Ge2026,
  author = {Ge, Zhiyi and Lian, Di and Zhao, Wei and Song, Weiru and Han, Shengyi and Xu, Chunyan},
  title = {Isolation, Characterization, and In Vivo Evaluation Efficacy of Lytic Bacteriophage SEP1 Against Salmonella Paratyphi C},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {751},
  doi = {10.3390/v18070751}
}
Kostenlos starten →